期刊文献+

影响多发性肌炎和皮肌炎疗效的因素分析和对策 被引量:2

Analysis and strategy of the factors that influence the efficacy of poly-myositis and dermatomyositis
暂未订购
导出
摘要 目的探讨影响多发性肌炎和皮肌炎疗效的因素和对策。方法通过对66例多发性肌炎和皮肌炎的临床资料和治疗方法进行分析。结果延误诊断、糖皮质激素用量不足和疗程不够、不及时加用免疫抑制剂、伴发肺间质病变或心肺功能差及恶性肿瘤是影响其疗效的因素。结论及早诊断,早期足量,尤其早期激素冲击并继之以长时间适当剂量糖皮质激素,及时加用其他免疫抑制剂、尽早发现肺间质疾病与排除恶性肿瘤,可提高疗效,改善预后。 Objective To study the analysis and strategy of the factors that influence the efficacy of polymyositis and dermatomyositis. Methods Through a retrospective analysis of 66 cases of polymyositis and dermatomyositis. Results Delay in diagnosis, glucocorticoid dosage and treatment are not enough, not timely with immunosuppressive agents, associated with interstitial lung disease, poor cardiopulmonary function, cancer are polymyositis and dermatomyositis efficacy factors. Conclusion Early diagnosis, early enough, especially early hormonal impact, followed by long - appropriate dose glucocorticoids, and in a timely manner with immunosuppressive agents, early detection of interstitial lung disease, early to rule out malignancy, these measures could improve the efficacy and improve the prognosis.
作者 张国俊
出处 《脑与神经疾病杂志》 2012年第6期431-433,共3页 Journal of Brain and Nervous Diseases
关键词 多发性肌炎 皮肌炎 疗效影响因素 Polymyositis Dermatomyositis Therapeutic factors
  • 相关文献

参考文献3

二级参考文献34

  • 1张宪忠,李柯娃,羊毅,肖波,谢光洁.多发性肌炎的临床病理与超微结构观察[J].临床神经病学杂志,1993,6(4):205-206. 被引量:3
  • 2刘明,刘银红,许贤豪,谭爱国,褚德发,丁纪兵,崔言文.影响多发性肌炎、皮肌炎患者预后的相关因素研究[J].中国神经免疫学和神经病学杂志,2005,12(3):143-147. 被引量:4
  • 3Mastaglia F L, Phillips B A. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria[ J]. Rheum Dis Clin North Am, 2002, 28(4) : 723 -741.
  • 4Bohan A, Peter J B. Polymyositis and dermatomyositis (first of two parts) [J]. N Engl J Med, 1975, 292(7): 344-347.
  • 5Bohan A, Peter J B. Polymyositis and dermatomyositis ( second of two parts) [J].N Engl J Med, 1975, 292(8): 403 -407.
  • 6Ario A, Kautianinen H, Hakala M. Prognosis anti mortality of polymyositis and dermatomyositis patients[ J ]. Clin Rheumatol, 2006, 25 (2) : 234 - 239.
  • 7Danko K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features-A longitudinal study of 162 cases[J]. Medcine(Bahimore) , 2004, 83(1): 35-42.
  • 8Naschitz J E, Rosner 1, Rozenbaum M, et al. Rheumatic syndromes: clues to occuh neoplasia[ J]. Semin Arthritis Rheum, 1999, 29( 1 ) : 43 - 55.
  • 9Huang Y L, Chen Y J, Lin M W, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide populationbased study[J]. Br J Dermatol, 2009, 161(4) : 854 -860.
  • 10Meyer O,Hayem G,Palazzo E,et al.Interstitial lung disease in polymyositis and dermatomyositis[J].Clin Exp Rheumatol,2005,23(5):724-732.

共引文献12

同被引文献33

  • 1黎威,莫成荣.浅谈多发性肌炎的从脾论治[J].辽宁中医药大学学报,2007,9(2):19-19. 被引量:9
  • 2O'Hanlon TP, Carrick DM, Amett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRBI and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians [ J 1. Medicine (Baltimore) , 2005, 84 (6) : 338-349. DOI : 10.1097/ 01. md. 0000189818. 63141.8.
  • 3Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies [ J ]. Rheum Dis Clin North Am, 2002,28(4) :891-916 .
  • 4Bohan A, Peter JB. Polymyositis and dermatomyositis ( first of two.parts) IJ~. N Engl J Med, 1975,292(7):344-347. DOI: I0. 1056/NEJM197502132920706.
  • 5Ch6rin P, Marie I. New diagnostic criteria and measuring outcome in polymyositis and dermatomyositis [ J ]. Rev Med Interne, 2005, 26 ( 5 ) : 361-367. DOI : 10.1016/j. revmed. 2005.02. 002.
  • 6G.erami P, Sehope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin6 myositis ): a missing link within the spectrum of the idiopathic inflammatory myopathies [ J ]. J Am Acad Dermatol, 2006,54(4) :597-613. DOI: 10. 1016/j. jaad. 2005.10. 041.
  • 7Tomasov6 SJ, Charvft F, Jarosov6 K, et al. The role of MRI in the assessment of polymyositis and dermatomyositis [ J ]. Rheumatology ( Oxford), 2007,46 ( 7 ) : 1174-1179. DOI: 10. 1093/rheumatology/kem088.
  • 8Tateyama M, Fujihara K, Misu T, et al. Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation [ J 1. BMJ Open, 2015,5 ( 1 ) : e006763. DOI: 10. l136/bmjopen-2014-006763.
  • 9Basu S, Zhuang H, Torigian DA, et al. Funetional imaging of inflammatory diseases using nuclear medicine techniques [ J ]. Semin Nuel Med, 2009, 39 (2) : 124-145. DOI: 10. 1053/j. semnuelmed. 2008.10. 006.
  • 10Okamura K, Yonemeto Y, Arisaka Y, et al. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG- PET/CT[ J 1. Rheumatology ( Oxford ) , 2012, 51 ( 8 ) : 1484- 1491. DOI: 10. 1093/rheumatology/kes064.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部